Axoltis Pharma Secures €18 million to Advance Blood-Brain Barrier Therapy for Charcot’s Disease
Table of Contents
A promising new approach to treating neurodegenerative diseases is gaining momentum as Axoltis Pharma,a French biotech company,has secured €18 million in Series A funding to accelerate the growth of its drug candidate,NX210c. The funding will be crucial for completing Phase II trials focused on Charcot’s disease, also known as amyotrophic lateral sclerosis (ALS), with the goal of restoring the compromised blood-brain barrier – a key factor in disease progression.
Pioneering a New Therapeutic Avenue for ALS
Charcot’s disease affects nearly 400,000 people worldwide, causing the progressive destruction of motor neurons and leading to debilitating loss of mobility and speech. Currently, there is no cure, and prognosis is grim, typically ranging from two to five years after diagnosis. This urgent unmet need has fueled investment in Axoltis’ innovative approach. The company’s lead candidate,NX210c,has already been designated an orphan drug by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), recognizing the critical importance of finding effective treatments for this rare and devastating condition.
How NX210c Aims to Restore Brain Health
NX210c is a peptide designed to address the underlying pathology of Charcot’s disease by rebuilding the damaged blood-brain barrier. This barrier is essential for protecting the brain and ensuring proper neuronal function. According to company materials, NX210c works thru a three-pronged approach: strengthening the integrity of the blood-brain barrier itself, improving synaptic transmission, and stimulating the brain’s natural neuroprotection systems.
Funding Structure and Phase II Trial Timeline
The €18 million investment is structured in two installments. The first tranche is instantly available to Axoltis, while the second is contingent upon the successful completion of the ongoing Phase II clinical trial. This trial, launched at the end of 2024, will evaluate the efficacy of NX210c in treating Charcot’s disease, with results anticipated in the second quarter of 2026. “While financing biotechs remains especially demanding, the success of this funding round demonstrates investors’ confidence in our strategy,” stated a senior official at Axoltis Pharma.
Crowdfunding and Investor confidence
The Series A round included both a capital increase and a successful crowdfunding campaign via the Capital Cell platform, attracting over 650 investors. This innovative fundraising method highlights growing investor interest in biotech and the potential of novel therapies. Axoltis was also recently nominated for the Gallien USA 2024 prize in the “Best start-up” category, further validating its promising research.
Beyond Charcot’s: Expanding Therapeutic Potential
While the initial focus is on Charcot’s disease, Axoltis envisions a broader request for NX210c. The drug’s mechanism of action – restoring the blood-brain barrier – coudl be beneficial in treating a range of other neurodegenerative conditions. The company is currently conducting a Phase I study evaluating NX210c in multiple sclerosis, and is also exploring potential applications in Alzheimer’s disease, Parkinson’s disease, and spinal cord injuries.
Strategic Partnerships and Future Outlook
Axoltis is actively pursuing partnerships with international pharmaceutical companies to accelerate the development and global distribution of NX210c. “This fundraising also allows us to continue our discussions with international pharmaceutical companies with a view to a global partnership which would, among other things, accelerate access to treatment for patients,” explained yann godfrin, chairman of the management board of Axoltis Pharma. the company’s innovative approach and strong early data position it as a key player in the fight against neurodegenerative diseases, offering hope for patients and families affected by these debilitating conditions.
Related reading
- Cholesterol Treatment Removes Forever Chemicals From Blood (newsy-today.com)
